InsiderPulseNo transactions found.
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $97.9M+31.3% | $74.6M |
| Cost of revenue | $11.6M-30.2% | $16.6M |
| Gross profit | $86.3M+48.9% | $58.0M |
| Sales and marketing | $13.4M+187.2% | $4.7M |
| General and administrative | $11.6M+39.5% | $8.3M |
| Research and development | $15.0M+369.7% | $3.2M |
| Depreciation and amortization | $335K+141.9% | $139K |
| Total operating expenses | $40.2M+147.4% | $16.3M |
| Income from operations | $46.1M+10.5% | $41.7M |
| Interest income | $46K-53.1% | $97K |
| Loss on disposition of assets | -$44K-25245.7% | -$175 |
| Gain (loss) on equity method investment in joint venture | -$430K-155.3% | $778K |
| Total other income (expense) | -$429K-149.0% | $875K |
| Income before income taxes | $45.6M+7.2% | $42.6M |
| Income tax provision | $9.0M+9815.6% | $91K |
| Net income | $36.7M-13.7% | $42.5M |
| Basic | $28.9M+8.1% | $26.7M |
| Diluted | $29.9M+6.8% | $28.0M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
Top Midday Gainers
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara